Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Valeant Pharmaceuticals Intl Inc. (VRX), Carter’s Inc. (CRI), Charter Communications Inc. (CHTR) Amongst Hound Partners Top Q2 Picks

Hound Partners, managed by Jonathan Auerbach, disclosed its equity positions for the second quarter of 2014. In a new filing with the U.S. Securities and Exchange Commission, the fund revealed holding 19 holdings, with a total market value of around $2.67 billion. The fund reduced stakes in five stocks and sold out three companies over the quarter.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

We will discuss three top positions of Hound Partners for the second quarter. Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) is represented as the top holding, in which Hound Partners upped its stake to 2.85 million shares from 2.43 million shares held previously. The market value of holding is $359.6 million.

Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products. The company’s total revenues for the second quarter of 2014 rose to $2.0 billion, compared to $1.1 billion for the second quarter of 2013, driven by strong growth in almost all of its businesses. It reported net income attributable to the company of $125.8 million, or $0.37 per diluted share, compared to $10.8 million, or $0.03 per diluted share, in the second quarter of 2013, according to press release.

On Wednesday, shares of the company rose by 1.62% to $109.82. The company has a market cap of $36.6 billion. Aside from Hound Partners, Valueact Capital, led by Jeffrey Ubben, holds 18.92 million shares, and Andreas Halvorsen’s Viking Global owns 9.30 million shares of Valeant Pharmaceuticals Intl Inc. (NYSE:VRX).

The second holding is Carter’s Inc. (NYSE:CRI), in which the fund revealed a $274.9 million stake, which contains 3.99 million shares. The stake represents an increase from 3.41 million shares the fund reported holding at the end of the first quarter.

With a market cap of $4.2 billion, Carter’s, Inc. (NYSE:CRI) is a U.S.-based branded marketer of apparel exclusively for babies and young children. The company reported a 31.6% increase in net income in the second quarter of fiscal 2014 to $25.9 million, or $0.48 per diluted share, compared to $19.7 million, or $0.33 per diluted share, in the same period of 2013.

Other hedge funds holding stakes in Carter’s, Inc. (NYSE:CRI) include Tiger Global Management LLC, led by Chase Coleman, which owns 6.49 million shares, and Alan Fournier’s Pennant Capital Management, which holds 3.18 million shares.

Third on the list is Charter Communications Inc. (NASDAQ:CHTR), a broadband communications company and cable operator in the United States. Hound Partners disclosed holding 1.55 million shares of the company, with a reported value of $246.2 million. At the end of the previous quarter, the fund reported owning 1.45 million shares of Charter Communications Inc. (NASDAQ:CHTR).

For the second quarter 2014, the company reported an increase in revenues to $2.3 billion, compared to $2 billion in the same period of 2013. Last month, Charter Communications Inc. (NASDAQ:CHTR) completed its acquisition of Cablevision’s Bresnan Broadband Holdings LLC and its subsidiaries. The acquisition helped the company to add cable operating systems in Montana, Wyoming, Colorado and Utah, according to a news release.

Other significant shareholders of the company include SPO Advisory Corp, led by John H. Scully, which disclosed ownership of 8.67 million shares, and William B. Gray’s Orbis Investment Management holding 3.25 million shares of the company.

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!